N/A
N=1,623
COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos)
Health Behavior · Health Care Utilization
Bottom Line
View on ClinicalTrials.gov: NCT04793464 ↗Enrolled (actual)
1,623
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: COVID-19 Prevention Health Behaviors 1 — 6.0; 6.7; 4.8 score on a scale — p=.26
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Promotores de Salud (Behavioral); Services as usual (Behavioral)
- Age
- Pediatric, Adult, Older Adult · 3+ yrs
- Sex
- All
- Sponsor
- University of Oregon
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY COVID-19 Prevention Health Behaviors 1 |
6.0; 6.7; 4.8 | .26 |
| PRIMARY COVID-19 Prevention Health Behaviors 2 |
1.4; 1.7; 2.1 | .02 sig |
| PRIMARY COVID-19 Knowledge and Attitudes 1 |
325; 187; 5 | .68 |
| PRIMARY COVID-19 Knowledge and Attitudes 2 |
335; 187; 6 | .44 |
| PRIMARY COVID-19 Knowledge and Attitudes 3 |
4.1; 4.1; 4.2 | .77 |
| PRIMARY COVID-19 Knowledge and Attitudes 4 |
2.5; 2.4; 2.6 | .66 |
| PRIMARY Attitudes Towards COVID-19 Vaccines |
4.6; 4.6; 4.7 | .44 |
| SECONDARY Broadband Internalizing Symptoms |
1.7; 1.9; 1.6 | 0.017 sig |
Summary
The global SARS-CoV-2 pandemic that causes the severe respiratory illness COVID-19 is the worst health crisis that the United States has faced in a century. Although this highly contagious virus has infected millions of Americans already, the disease burdens are disproportionately born by historically underserved populations such as Latinx communities. This disparity is notable in Oregon, where the 13% of the population that is Latinx represents approximately 44% of COVID-19 cases. An urgent need exists to reach Oregon's Latinx community to prevent SARS-CoV-2 transmission.
The overall goal of this study is to implement a Promotores de Salud intervention to increase the reach, access, uptake, and impact of testing in Latinx communities in Oregon. This project will fully integrate with the National institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) consortium and its Coordination and Data Collection Center (CDCC). With guidance and leadership from the study's Latinx Community and Scientific Advisory Board, 38 testing sites have been established to test the Promotores de Salud intervention. The investigators will test whether the Promotores de Salud intervention will increase testing rates and promote better health behaviors in communities over time. The investigators will test the intervention using a randomized control trial comparing the intervention to county outreach services as usual. Evaluation of the Promotores de Salud intervention held during a testing event (compared to distribution of a pamphlet only) will test whether culturally competent education results in greater use of strategies that reduce transmission of COVID-19 at the community and individual level.
The investigators have designed a working group structure with teams focused on: Community Engagement, Molecular Biology, Data Science, and Implementation Science. These working groups are coordinated by an Administrative Hub and guided by the study's Latinx Community and Scientific Advisory Board.
Over time, this project will help communities institutionalize optimal local testing frameworks supported by University of Oregon laboratory facilities for testing capacity, technical support for testing logistics, and collection of data on health behaviors, testing rates, and sustainability. The resulting structures and systems will be poised for future scale-up to other vulnerable communities and/or for other public health purposes (e.g., vaccination campaigns).
Eligibility Criteria
Inclusion Criteria
- Proportion Tested: Age 3 or older
- Proportion Tested: Received testing at study testing site
- Individual Survey: 15 or older
Exclusion Criteria
- Individual Survey: Unable to understand Spanish or English or another language translated by a qualified translator at a 5th grade level
Data sourced from ClinicalTrials.gov (NCT04793464). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.